Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 30 years of experience in the Korean/Asian equity research. Major sectors coverage include the following:
- Technology 
- Consumer 
- Special Situations/Deep Value Plays
- Tender Offers/M&As
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

KOSDAQ150 Rebalance Preview: The Final Cut

Companies With No Research in KRX300 - Search for Alpha

A Review of Rights Offerings/Capital Raise Announcements in Korea in 2024

Hyundai Motor Securities Announces a Rights Offering Involving a 49% Shares Dilution

Korea Zinc - Rights Offering of 2.5 Trillion Won Is a Display Of "Korea Discount" At Its Worst

Douglas Research Advisory

Event-Driven

<ul>
<li>On 20 December, Chabiotech (085660 KS) announced that it plans to conduct a rights offering capital raise of 250 billion won. </li>
<li>The expected rights offering price is 10,800 won (27.3% lower than current price of 14,860 won). A total of 23.148 million new shares (41% of outstanding shares) will be issued.</li>
<li>This capital raise by CHA Biotech is likely to further negatively impact the company's share price in the next several weeks as many investors are concerned about excessive shares dilution. </li>
</ul>


On 20 December, Chabiotech (085660 KS) announced that it plans to conduct a rights offering capital raise of 250 billion won. 
The expected rights offering price is 10,800 won (27.3% lower than current price of 14,860 won). A total of 23.148 million new shares (41% of outstanding shares) will be issued.
This capital raise by CHA Biotech is likely to further negatively impact the company's share price in the next several weeks as many investors are concerned about excessive shares dilution. 


CHA Biotech Announces A Capital Raise of 41% of Outstanding Shares